Publications by authors named "S L Cohan"
The study examined changes in the plasma proteome, metabolome, and lipidome of N = 14 patients with relapsing-remitting multiple sclerosis (RRMS) initiating treatment with ocrelizumab, assayed at baseline, 6 months, and 12 months. Analyses of >4000 circulating biomarkers identified depletion of B-cell associated proteins as the early effect observed following ocrelizumab (OCR) initiation, accompanied by the reduction in plasma abundance of cytokines and cytotoxic proteins, markers of neuronaxonal damage, and biologically active lipids including ceramides and lysophospholipids, at 6 months. B-cell depletion was accompanied by decreases in B-cell receptor and cytokine signaling but a pronounced increase in circulating plasma B-cell activating factor (BAFF).
View Article and Find Full Text PDFArticle Synopsis
- Melatonin is studied for its potential role in managing multiple sclerosis (MS) by acting as an antioxidant and modulating the immune system, but its effects on MS patients are still not well understood.
- The objective of the study was to assess whether melatonin supplementation leads to higher levels of melatonin in the body and if it positively affects patient-reported outcomes.
- The study involved 30 individuals with relapsing forms of MS, showing that a higher dose (5 mg) resulted in increased melatonin levels compared to a lower dose (3 mg), but there were no significant improvements in fatigue or quality of life measures over 12 months.
Background And Objectives: Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse groups may be higher; however, these populations are under-represented in MS trials. This post hoc analysis compared the proportion of patients achieving 3-parameter no evidence of disease activity (NEDA-3) with ofatumumab vs teriflunomide in participants with relapsing MS (RMS) enrolled in the ASCLEPIOS I/II trials by race/ethnicity subgroup.
View Article and Find Full Text PDFIntroduction: No validated algorithm exists to identify patients with neuromyelitis optica spectrum disorder (NMOSD) in healthcare claims data. We developed and tested the performance of a healthcare claims-based algorithm to identify patients with NMOSD.
Methods: Using medical record data of 101 adults with NMOSD, multiple sclerosis (MS), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), we tested the sensitivity and specificity of claims-based algorithms developed through interviews with neurologists.
Article Synopsis
- A new test called the Multiracial Reading the Mind in the Eyes Test (MRMET) was developed to be more inclusive than the original Reading the Mind in the Eyes Test (RMET), incorporating diverse racial stimuli and non-gendered options.
- The MRMET has been shown through extensive testing to match or outperform the RMET in key psychometric measures, making it a reliable assessment tool for social cognition.
- Both tests yield interchangeable results, reinforcing that inclusion in psychometric assessments is not only possible but also effective; the MRMET and its validation data are openly accessible online.